Femasys Q1 sales up 25.9% but net loss widens to $5.9M; cash runway only into early Q3 2025

FEMASYS INC

2025-Q1 EPS reported -$0.23 revenue$341,264

Sales increased 25.9% YoY to $341K, driven by FemaSeed sales.
Net loss widened to $5.9M ($0.23 per share) from $3.6M ($0.17) in prior year.
R&D expenses surged 67.6% to $2.97M, mainly due to regulatory and development costs.
Cash and equivalents $3.8M; company expects to fund operations only into early Q3 2025.
FemBloc delivery system received CE mark recommendation in Europe; FemaSeed partnerships expanded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.